Chiasma Inc [NASDAQ:CHMA] has been among the top performing stocks in the last one year. Besides, at press time CHMA is trending up 1.71% with daily change of about +0.10. The price has achieved an intraday low of $5.94 and an intraday high of $5.96. According to the data by Barchart, CHMA previously closed at $5.84 with a volume of $114,500. In the last one year, CHMA achieved a +293.40 (Weighted Alpha). Moreover, it has a 52-week range between 1.20 – 7.19 while maintaining a stochastic of 70.97%.
The fundamentals show that it has a market capitalization of $145,322 and outstanding shares amounting to 24,465. According to the analysis rating/earnings estimate CHMA is still has a strong buy signal. In the last one month the stock has corrected higher +31.71% while it has grown +80.00 and a performance +58.40% since January 2019. In times of price performance CHMA stock has grown by +395% recording an average performance of +309.66.
Analysts on the market are expecting CHIASMA, INC. (CHMA) to be released on May 9, 2019. The expected report will take care of the fiscal period ending March 31, 2019. The reported EPS for the same period last year was -$.29. According to the estimated EPS the prediction for the next financial year is at -$1.18 which is likely to be released on March 13, 2020.
Chiasma, Inc. is a clinical-stage biopharmaceutical firm that concentrates improving the lives of patients that are suffering from rare and serious chronic diseases. On April 1, the company said that had closed its previously announced underwritten public offering of 7,263,158 shares for its common stock at the cost of $4.75 per share in order to raise a gross of about $34.5 million.
Among these shares, 947,368 of them are common stocks sold pursuant to the option given by Chiasma to the underwriters; an option that was exercised to its entirety. The company plans to use the revenue from the shares to support various development costs including its ongoing phase 3 clinical trials of octreotide capsules as well as the plan for its commercialization in the U.S.
According to GlobeNewswire:
“The offering was made pursuant to a shelf registration statement on Form S-3 (File No. 333-223850), including a base prospectus, filed by Chiasma on March 22, 2018 and declared effective by the Securities and Exchange Commission, or the SEC, on May 3, 2018. The offering was made only by means of a prospectus. A final prospectus supplement relating to and describing the terms of the offering was filed with the SEC on March 29, 2019 and is available on the SEC’s website at www.sec.gov.”
Chiasma, Inc. (Nasdaq:CHMA) as mentioned is a medical research company that concentrates on the improvement of patients’ lives that have fallen victim to rare as well as dire chronic diseases. The company leverages its Transient Permeability Enhancer (TPE) technology to come up with oral medication that currently are only produced in injections. Its ongoing Phase 3 of the CHIASMA OPTIMAL was started in 2017 and has been given a trade-name MYCAPSSA. It supports the therapy of adult patients that suffer from acromegaly.
Chiasma has its headquarters in Waltham, MA in addition to a fully owned subsidiary in Israel. Its registered trademarks include MYCAPSSA, TPE and CHIASMA.